Clinical trials: Estrogen Therapy
Vaginal Infection, Urinary Tract Infection
Vaginal Estrogen With Pessary Treatment
Patients presenting with pelvic organ prolapse will be offered the use of a pessary. Vaginal estrogen cream treatment with the pessary will be randomized amongst the patients and patient satisfaction and complication rates will…
- Conditions
- Vaginal Infection, Urinary Tract Infection, Quality of Life
- Trial name
- NCT01843166
- Testing
- Premarin vaginal cream
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Postmenopausal
Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route
The aim of this pilot study conducted in post-menopausal women is to evaluate the effect of 17ß-estradiol administration on inflammatory-immune cells, namely antigen-presenting cells (monocytes/dendritic cells), and more…
- Trial name
- NCT00701337
- Testing
- oestradiol
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Toulouse
Braest Cancer, Dry Eye
Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment
Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes.
- Trial name
- breast cancer (NCT06924229)
- Testing
- Hormonal treatment
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sohag University
Covid19
Estradiol and Progesterone in Hospitalized COVID-19 Patients
The purpose of this study is to determine to what extent a short systemic steroid therapy with estradiol and progesterone, administered early to hospitalized and confirmed COVID-19 positive patients of both sexes in addition to…
- Trial name
- NCT04865029
- Testing
- Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tulane University
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence.
- Trial name
- NCT00002976
- Testing
- conjugated estrogens
- Where
- 149 sites in United States
- Volunteers
- 2,108 people
- Sponsor
- Gynecologic Oncology Group
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
This phase II trial evaluates the effect of capecitabine on tumor response using imaging and tumor markers to adjust dose (adaptive therapy) in patients with estrogen receptor (ER) positive, HER2 negative breast cancer that has…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, Metastatic HER2-Negative Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT06525766
- Testing
- Biospecimen Collection, Bone Scan, Capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with…
- Trial name
- NCT06428396
- Testing
- Belzutifan, Fulvestrant, Everolimus
- Where
- 41 sites in United States, Argentina and 7 more
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Pain
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia
The purpose of this study is to determine the effect of toremifene treatment to the MRI findings of the breast in women suffering from premenstrual mastalgia.
- Trial name
- NCT00534846
- Testing
- toremifene
- Where
- Finland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Satakunta Central Hospital
Inguinal Hernia Unilateral, Inguinal Hernia Bilateral
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias.
- Conditions
- Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
- Trial name
- RIGHT (NCT07604272)
- Testing
- Fulvestrant, Anastrozole (ARIMIDEX™)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Fibromyalgia
Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia
In order to evaluate the potential effects of estrogen treatment in postmenopausal women with fibromyalgia, the investigators used quantitative sensory tests before and after eight weeks of estrogen treatment as compared with…
- Trial name
- NCT01087593
- Testing
- 17β-estradiol
- Where
- Sweden
- Volunteers
- 29 people
- Sponsor
- Ostergotland County Council, Sweden
Advanced Solid Tumors, Advanced Breast Cancer
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
- Trial name
- NCT06993844
- Testing
- ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
- Where
- 15 sites in United States, China
- Volunteers
- 233 people
- Sponsor
- Ensem Therapeutics
Menopause, Platelet-rich Plasma
Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause
The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems.
- Conditions
- Menopause, Platelet-rich Plasma, Estrogen Replacement Therapy, Vaginal Atrophy
- Trial name
- NCT05483634
- Testing
- Vaginal estrogen supplement, Platelet-rich plasma injection
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Mackay Memorial Hospital
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
This phase II trial studies how well pembrolizumab and doxorubicin hydrochloride works compared to pembrolizumab with anti-estrogen therapy (anastrozole, letrozole, or exemestane) in treating patients with triple-negative or…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT02648477
- Testing
- Anastrozole, Doxorubicin Hydrochloride, Exemestane
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
Systematic assessment of survival data of patients who have been tested with EndoPredict®; prospective proof that patients with low risk classification by EndoPredict® (EPclin) can safely forgo chemotherapy and be treated with…
- Conditions
- Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative Tumor
- Trial name
- RESCUE (NCT03503799)
- Testing
- Observation
- Where
- 40 sites in Germany, Switzerland
- Volunteers
- 1,191 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Transgender Persons
Effect of Estrogen Treatment on Drug Metabolism and Transport
This project will evaluate the effect of estrogen treatment on how other medications are processed by the body.
- Trial name
- NCT05469204
- Testing
- Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Washington
Periodontal Diseases, Periodontal Pocket
Predictors of Periodontal Outcomes Post-sanative Therapy
Periodontal disease is a chronic inflammatory disease of the tissues surrounding the teeth and is one of the leading causes of tooth loss.
- Trial name
- NCT04639661
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Brock University
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
This randomized phase II trial studies how well mucoadhesive oral wound rinse works in preventing and treating stomatitis in patients with estrogen receptor (ER)- or progesterone receptor (PR)-positive metastatic or locally…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer
- Trial name
- NCT02015559
- Testing
- mucoadhesive oral wound rinse, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian…
- Conditions
- Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)
- Trial name
- MATAO (NCT04111978)
- Testing
- Letrozole 2.5mg
- Where
- 53 sites in Austria, Germany and 1 more
- Volunteers
- 540 people
- Sponsor
- Swiss GO Trial Group